We aimed to assess whether the breast-cancer intermediate-risk genes CHEK2, ATM ant TP53 were subject to differential allelic expression (DAE) in lymphoblastoid cell lines (LCLs) from high-risk breast cancer patients for whom no mutation in BRCA1 or BRCA2 had been identified.We implemented an assay based on high-resolution melting curve analysis (HRM) of single labeled fluorescent probes to detect allelic expression imbalance. The method relies on the distinction of the two alleles of an exonic marker SNP in heterozygous individuals with a fluorescent signal correlated to the relative abundance of each transcript. We developed an analysis tool for HRM data processing, specifically dedicated to DAE assessment. In our series, we found evidence for DAE for CHEK2, in carriers of the truncating mutation 1100delC. When combining mutation-screening data and assessment of DAE, we did not identify functional regulatory variant located in cis of the studied genes that would lead to DAE, in the transcriptional regulatory milieu of freely proliferating LCLs. Our results support that HRM is a method with high sensitivity and accuracy that can be used for DAE assessment. This approach can be applied to study breast and blood tissue samples. The latter would be of great interest for high-throughput mutation screening projects aiming to identify dysfunctional regulatory variants in candidate genes.

Osteoarthritis (OA) is a common, multifactorial disease that is characterized by focal degeneration of the smooth articular cartilage in any of the synovial joints. Although the underlying molecular mechanisms for OA are still not fully understood, epidemiological studies have evidenced a significant genetic component to OA susceptibility. Genome-wide linkage scans and large-scale association studies have had success in unraveling the genetic architecture underlying OA with the identification of a number of susceptibility genes. In this work, functional analyses are reported of OA associated polymorphisms within two susceptibility genes: BMP5 and GDF5, both members of the TGF-β superfamily of secreted proteins. The extent of differential allelic expression (DAE) of BMP5 in human mesenchymal tissues was first examined with significant differences in BMP5 allelic output observed (allelic ratios exceeding 4:1 in the tissues of some donors). Significant variability in allelic expression within the different tissues of donors was also observed, suggesting that polymorphism in cis-regulation of BMP5 expression is common and that there is a considerable effect of tissue specific elements on BMP5 expression. DAE was then used as a phenotype to map tissue-specific cis-regulatory polymorphisms with the identification of a single nucleotide polymorphism (SNP) located downstream of BMP5 that was significantly associated with DAE as well as OA, suggesting that variability in cis-regulation of BMP5 is important in OA susceptibility. Moreover, the functional effect of a previously identified OA associated microsatellite within intron 1 of BMP5 was investigated using luciferase reporter assays and electrophoretic mobility shift assays (EMSAs) with significant differences observed both in the ability of various microsatellite alleles to modulate BMP5 promoter activity and to bind GATA-3 nuclear proteins, further suggesting a role for variability in BMP5 expression in OA susceptibility that may in part be due to altered GATA-3 binding. Finally, functional characterization of a previously reported OA associated SNP in the 5′ UTR of GDF5 is presented in which EMSAs show differential binding of nuclear factors between the two SNP alleles, strengthening the possible functional contribution of this SNP to OA susceptibility. Overall, this work demonstrates that polymorphism in cis-regulation is likely to play a role in OA susceptibility.

Nous avons voulu évaluer si les gènes CHE2, ATM et TP53, associés à un risque intermédiaire de cancer du sein, étaient soumis à une différence d'expression allélique (DEA). Nous avons étudié des lignées cellulaires lymphoblastiques (LCLs) dérivées de patientes à haut risque, négatives pour des mutations dans CRCA1 et BRCA2. Nous avons développé une méthode basée sur la "fusion haute-résolution" (High-resolution melting curve analysis, HRM) et l'utilisation d'une sonde d'hybridation fluorescente pour détecter de la DEA chez des individus hétérozygotes pour un SNP marqueur exonique. Cette méthode permet de corréler le signal fluorescent à la quantité relative des transcrits alléliques. Nous avons développé un outil d'analyse adapté aux besoins spécifiques de l'étude de la DEA par HRM. Dans nos échantillons, une DEA statistiquement significative a été identifiée pour le gène CHEK2, chez les porteurs de la mutation tronquante 1100delC. En revanche, en combinant les données du criblage mutationnel des gènes candidats et de l'étude de DEA, nous n'avons pas identifié de variant régulateur localisé en cis qui induirait de la DEA significative dans les gènes étudiés, dans le contexte de régulation transcriptionnelle propre aux LCLs proliférant librement. Nos résultats montrent que le HRM est une méthode sensible et précise pour mesurer de la DAE et qui peut être appliquée à d'autres tissus, mammaires ou sanguins. Ces derniers présentent un grand intérêt pour les études de criblage mutationnel à haut-débit cherchant à identifier des variants dysfonctionnels dans les régions régulatrices de gènes candidats. / We aimed to assess whether the breast-cancer intermediate-risk genes CHEK2, ATM ant TP53 were subject to differential allelic expression (DAE) in lymphoblastoid cell lines (LCLs) from high-risk breast cancer patients for whom no mutation in BRCA1 or BRCA2 had been identified.We implemented an assay based on high-resolution melting curve analysis (HRM) of single labeled fluorescent probes to detect allelic expression imbalance. The method relies on the distinction of the two alleles of an exonic marker SNP in heterozygous individuals with a fluorescent signal correlated to the relative abundance of each transcript. We developed an analysis tool for HRM data processing, specifically dedicated to DAE assessment. In our series, we found evidence for DAE for CHEK2, in carriers of the truncating mutation 1100delC. When combining mutation-screening data and assessment of DAE, we did not identify functional regulatory variant located in cis of the studied genes that would lead to DAE, in the transcriptional regulatory milieu of freely proliferating LCLs. Our results support that HRM is a method with high sensitivity and accuracy that can be used for DAE assessment. This approach can be applied to study breast and blood tissue samples. The latter would be of great interest for high-throughput mutation screening projects aiming to identify dysfunctional regulatory variants in candidate genes.

No description available.